Business Context and Reporting Period
Tvardi Therapeutics, Inc. (TVRD) is a clinical-stage biopharmaceutical company focused on developing oral, small molecule STAT3 inhibitors for inflammatory and proliferative diseases. The reporting period covers the fiscal year ended December 31, 2025. In April 2025, the company completed a reverse merger with Cara Therapeutics, Inc., changing its name to Tvardi Therapeutics, Inc. The company has no approved products and has not generated any revenue to date.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(18.2) million | $(29.4) million |
| Operating Expenses | $26.7 million | $28.1 million |
| Cash and Cash Equivalents | $20.7 million | $31.6 million |
| Short-term Investments | $10.1 million | $0 |
| Accumulated Deficit | $(110.5) million | $(92.2) million |
| Debt | $0 (Convertible Notes converted to equity in Q2 2025) | $30.3 million (Convertible Notes) |
Note: The 2025 net loss includes a $7.8 million net gain from the change in fair value of Convertible Notes prior to their conversion.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by 38.0% to $18.2 million in 2025 compared to $29.4 million in 2024. This improvement was primarily driven by a $7.8 million net gain on the fair value remeasurement of Convertible Notes and a reduction in Research and Development (R&D) expenses.
- R&D Expenses: R&D expenses decreased by 23.8% to $18.0 million. This was due to reduced costs in the HCC, metastatic breast cancer (mBC), and IPF trials for TTI-101, partially offset by a 350.2% increase in costs for the new TTI-109 program ($5.4 million).
- G&A Expenses: General and Administrative expenses increased by 96.0% to $8.7 million, driven by higher professional fees ($2.0 million increase) related to the Merger and public company compliance.
- Liquidity: The company acquired approximately $23.9 million in net assets through the Merger with Cara Therapeutics in April 2025. However, cash and cash equivalents decreased year-over-year due to operating cash outflows and investing activities.
Guidance, Outlook, and Risks
Outlook and Clinical Progress:
- TTI-101 (HCC): The company is enrolling patients in the REVERT LIVER CANCER Phase 1b/2 trial. The anticipated data readout has been extended from the first half of 2026 to the second half of 2026 to allow for data maturation and dose optimization.
- TTI-101 (IPF): In October 2025, the company reported that the Phase 2 trial in Idiopathic Pulmonary Fibrosis did not meet its primary goals. However, post-hoc analyses of a subset of patients showed reductions in fibrosis and inflammatory markers, providing proof of concept for the mechanism.
- TTI-109: A Phase 1 trial in healthy volunteers was initiated in Q3 2025. Topline data is expected in Q2 2026, after which the company intends to announce the next clinical indication.
Risks and Contingencies:
- Going Concern: Management has concluded that conditions raise substantial doubt about the company's ability to continue as a going concern. The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to fund operations and clinical trials.
- Internal Controls: The company identified material weaknesses in its internal control over financial reporting, including inadequate review of financial statements, lack of formal risk assessment, and insufficient segregation of duties. Remediation efforts are underway.
- Capital Requirements: The company has no committed external funding sources. Failure to raise additional capital could force the delay or termination of clinical programs.
Key Facts for Investor Verification
- Going Concern Status: Verify the company's ability to secure additional funding, as current cash resources ($30.8 million total liquid assets) may not be sufficient to fund operations for the next 12 months.
- IPF Trial Results: Review the detailed post-hoc analysis of the REVERT IPF Phase 2 trial to understand the basis for the "proof of concept" claims despite the study not meeting primary goals.
- Internal Control Remediation: Monitor the progress of remediation efforts for the identified material weaknesses in internal controls over financial reporting.
- TTI-109 Development: Track the Q2 2026 topline data release for the TTI-109 Phase 1 trial, which will determine the next development indication.
- Convertible Note Conversion: Confirm the impact of the $28.3 million Convertible Notes conversion into equity on shareholder dilution and capital structure.